US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mural Oncology

2.69

-0.0100-0.37%

Post-market: 2.64-0.0500-1.86%18:31 EDT

Volume:1.37M

Turnover:3.64M

Market Cap:46.34M

PE:-0.35

High:2.79

Open:2.60

Low:2.55

Close:2.70

Loading ...

Overview Company News Filings

JonesTrading Downgrades Mural Oncology to Hold From Buy

MT Newswires Live

BRIEF-Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab)

BUZZ-Mural Oncology slumps after halting ovarian cancer drug trials

Mural Oncology Plc : Jonestrading Cuts to Hold Rating

THOMSON REUTERS

Mural Oncology to Discontinue Ovarian Cancer Drug Candidate as Trial Misses Targets

Mural Oncology Shares Down 22.2% Premarket After Co to Stop Development of Drug for Ovarian Cancer

THOMSON REUTERS

Mural- Based on Overall Survival Data Observed in Interim Analysis in Platinum-Resistant Ovarian Cancer, to Not Progress Trial to Final Analysis

THOMSON REUTERS

Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer

This Week's Unlock Schedule: SOLV, APE, and OM to Experience Large One-time Vesting

Mural Oncology Q4 2024 GAAP EPS $(2.01) Misses $(1.96) Estimate

Mural Oncology Plc: Cash Runway Extended Into Q1 2026 Through Operational Efficiencies

THOMSON REUTERS

Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference

We Think Mural Oncology (NASDAQ:MURA) Needs To Drive Business Growth Carefully

Simply Wall St.

Promising Prospects for Mural Oncology: Buy Rating Justified by Strong Pipeline and Financial Position

Mural Oncology Initiated at Buy by Jones Trading

Mural Oncology Advances Drug Pipeline and Extends Runway

Mural Oncology Achieves Required Overall Survival Events in Trial, Extends Cash Runway

MT Newswires Live

Mural Oncology Plc -Company Extends Cash Runway Projection Into Q1 2026 Through Operational Efficiencies

THOMSON REUTERS

Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/MURA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MURA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MURA\",,,,,undefined,":{"symbol":"MURA","market":"US","secType":"STK","nameCN":"Mural Oncology","latestPrice":2.69,"timestamp":1745265600000,"preClose":2.7,"halted":0,"volume":1371170,"hourTrading":{"tag":"盘后","latestPrice":2.64,"preClose":2.69,"latestTime":"18:31 EDT","volume":6411,"amount":17208.2093823,"timestamp":1745274677647},"delay":0,"floatShares":11823307,"shares":17228291,"eps":-7.5799,"marketStatus":"Post-Mkt","change":-0.01,"latestTime":"04-21 18:33:32 EDT","open":2.6,"high":2.79,"low":2.55,"amount":3635604.602072,"amplitude":0.088889,"askPrice":2.65,"askSize":1,"bidPrice":2.64,"bidSize":225,"shortable":3,"etf":0,"ttmEps":-7.5799,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1745280000000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":2.7,"preHourTrading":{"tag":"盘前","latestPrice":2.58,"preClose":2.7,"latestTime":"09:28 EDT","volume":88606,"amount":230314.9403324,"timestamp":1745242118197},"postHourTrading":{"tag":"盘后","latestPrice":2.64,"preClose":2.69,"latestTime":"18:31 EDT","volume":6411,"amount":17208.2093823,"timestamp":1745274677647},"volumeRatio":0.025009,"impliedVol":0.689,"impliedVolPercentile":0.2704},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MURA\",,,,,undefined,":{"symbol":"MURA","floatShares":11823307,"roa":"-36.68%","roe":"-63.57%","lyrEps":-7.5799,"volumeRatio":0.025009,"shares":17228291,"dividePrice":0,"high":2.79,"amplitude":0.088889,"preClose":2.7,"low":2.55,"week52Low":0.95,"pbRate":"0.33","week52High":4.74,"institutionHeld":0,"latestPrice":2.69,"committee":0.99115,"eps":-7.5799,"divideRate":0,"volume":1371170,"delay":0,"ttmEps":-7.5799,"open":2.6,"prevYearClose":3.22,"prevWeekClose":2.7,"prevMonthClose":1.26,"prevQuarterClose":1.26,"fiveDayClose":1.03,"twentyDayClose":3.85,"sixtyDayClose":3.92},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MURA\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2522878022","title":"JonesTrading Downgrades Mural Oncology to Hold From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2522878022","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522878022?lang=en_us&edition=fundamental","pubTime":"2025-03-25 20:00","pubTimestamp":1742904010,"startTime":"0","endTime":"0","summary":"Mural Oncology (MURA) has an average rating of buy and mean price target of $16, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MURA"],"gpt_icon":0},{"id":"2522024589","title":"BRIEF-Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab)","url":"https://stock-news.laohu8.com/highlight/detail?id=2522024589","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522024589?lang=en_us&edition=fundamental","pubTime":"2025-03-25 19:49","pubTimestamp":1742903366,"startTime":"0","endTime":"0","summary":"BRIEF-Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA (pembrolizumab)March 25 (Reuters) - Mural Oncology PLC MURA.O:MURAL ONCOLOGY PROVIDES UPDAT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nTUA7QZMJV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MURA","BK4139"],"gpt_icon":0},{"id":"2522802167","title":"BUZZ-Mural Oncology slumps after halting ovarian cancer drug trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2522802167","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522802167?lang=en_us&edition=fundamental","pubTime":"2025-03-25 19:44","pubTimestamp":1742903079,"startTime":"0","endTime":"0","summary":"BUZZ-Mural Oncology slumps after halting ovarian cancer drug trials** Mural Oncology's shares MURA.O slump 39.7% to $2.31 premarket ** MURA says it is stopping late-stage trials testing its experiment","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nL4N3PV0PM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1941712348.USD","LU1974910355.USD","LU1917777945.USD","IE00B4R5TH58.HKD","SG9999001440.SGD","BK4585","BK4139","BK4550","LU1037948541.HKD","LU1934455277.USD","LU1989771016.USD","LU2023250843.SGD","MRK","LU0320765646.SGD","LU1066051811.HKD","SG9999014542.SGD","LU1162221912.USD","LU1037948897.HKD","BK4588","LU0965508806.USD","LU1023059063.AUD","LU1585245621.USD","LU1929549753.HKD","BK4534","SG9999014567.USD","LU1035773651.USD","IE00B1BXHZ80.USD","BK4559","LU1093756325.SGD","LU0265550359.USD","SG9999014559.SGD","LU0234572021.USD","LU0965509010.AUD","LU2112291526.USD","LU1066051498.USD","LU1934455863.HKD","LU0965509101.SGD","LU0965509283.SGD","LU2361044949.HKD","LU1061106388.HKD","IE00BN8TJ469.HKD","LU1069347547.HKD","SG9999015358.SGD","LU1983299246.USD","MURA","LU2361044865.SGD","SGXZ57979304.SGD","LU0861579265.USD","LU0122379950.USD","IE000M9KFDE8.USD"],"gpt_icon":0},{"id":"2522029114","title":"Mural Oncology Plc : Jonestrading Cuts to Hold Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2522029114","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522029114?lang=en_us&edition=fundamental","pubTime":"2025-03-25 19:35","pubTimestamp":1742902526,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q811D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MURA"],"gpt_icon":0},{"id":"2522023187","title":"Mural Oncology to Discontinue Ovarian Cancer Drug Candidate as Trial Misses Targets","url":"https://stock-news.laohu8.com/highlight/detail?id=2522023187","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522023187?lang=en_us&edition=fundamental","pubTime":"2025-03-25 19:08","pubTimestamp":1742900880,"startTime":"0","endTime":"0","summary":"Mural Oncology said that it won't continue developing its ovarian cancer drug candidate Nemvaleukin to be used in conjunction with Merck's Keytruda after results showed no statistical improvement in survival.The clinical-stage immuno-oncology company said Tuesday that it won't continue to final analysis and cease development of nemvaleukin, its drug that was aimed to treat platinum-resistant ovarian cancer.This particular ovarian cancer is resistant to platinum-based chemotherapy treatments which are commonly the first option.Mural Oncology said the Artistry-7 phase 3 trial of nemvaleukin alfa in combination with Merck's anti-PD-1 therapy, Keytruda, didn't achieve a statistically significant improvement in overall survival compared with chemotherapy alone.Shares of Mural were over 26% lower in premarket trading at $2.82.The treatment is still being evaluated in a phase 2 trial to treat mucosal melanoma. The company said it expects to share its data readout in the second quarter.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","LU1989772840.SGD","LU2361044949.HKD","IE00B1BXHZ80.USD","LU0265550946.USD","SG9999014542.SGD","LU1917777945.USD","LU1934455277.USD","LU1585245621.USD","IE00BLSP4452.SGD","LU1974910355.USD","MURA","LU0058720904.USD","LU0861579265.USD","LU1023059063.AUD","LU2361044865.SGD","SG9999014575.USD","LU0965508806.USD","MRK","LU1116320737.USD","LU0203347892.USD","LU1291159041.SGD","BK4516","BK4585","LU1069347547.HKD","IE0009355771.USD","LU1162221912.USD","LU1066051811.HKD","SG9999001176.SGD","SG9999015358.SGD","IE00BN8TJ469.HKD","LU0070302665.USD","LU1066053197.SGD","LU1430594728.SGD","LU0320765646.SGD","IE0002141913.USD","LU0266013472.USD","LU2112291526.USD","LU0265550359.USD","LU1061106388.HKD","SGXZ57979304.SGD","LU1989772923.USD","IE00BJT1NW94.SGD","LU0965509283.SGD","IE00BJJMRZ35.SGD","LU1066051225.USD","LU1941712264.USD","LU1035773651.USD","LU1093756325.SGD","LU2089984988.USD"],"gpt_icon":0},{"id":"2522604269","title":"Mural Oncology Shares Down 22.2% Premarket After Co to Stop Development of Drug for Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2522604269","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522604269?lang=en_us&edition=fundamental","pubTime":"2025-03-25 18:38","pubTimestamp":1742899106,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q807B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MURA","BK4139"],"gpt_icon":0},{"id":"2522704425","title":"Mural- Based on Overall Survival Data Observed in Interim Analysis in Platinum-Resistant Ovarian Cancer, to Not Progress Trial to Final Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2522704425","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522704425?lang=en_us&edition=fundamental","pubTime":"2025-03-25 18:30","pubTimestamp":1742898600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nTUA7QZMJV:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MURA"],"gpt_icon":0},{"id":"2522059071","title":"Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2522059071","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522059071?lang=en_us&edition=fundamental","pubTime":"2025-03-25 18:30","pubTimestamp":1742898600,"startTime":"0","endTime":"0","summary":"Based on overall survival data observed in interim analysis in platinum-resistant ovarian cancer, Mural will not progress trial to final analysis. Continued demonstration of favorable tolerability profile generally consistent with previously reported data; over 800 patients treated across the greater nemvaleukin clinical program. The company remains on track to share topline results from potentially registrational, phase 2 trial in mucosal melanoma, ARTISTRY-6, Cohort 2, evaluating nemvaleukin monotherapy in Q2 2025. Nemvaleukin is currently being evaluated in a potentially registrational, phase 2 trial, ARTISTRY-6, cohort 2 in mucosal melanoma, with a topline data readout expected in Q2 2025. Preliminary data readouts for less-frequent intravenous dosing of nemvaleukin in patients with cutaneous melanoma are expected in the second quarter of 2025 for cohort 3 of ARTISTRY-6  and the second half of 2025 for cohort 4 of ARTISTRY-6 , subject to patient enrollment.KEYTRUDA is a registered ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mural-oncology-provides-phase-3-103000352.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1929549753.HKD","BK4533","LU2112291526.USD","LU1066051498.USD","LU2461242641.AUD","IE00BLSP4452.SGD","LU1057294990.SGD","LU1974910355.USD","LU0238689110.USD","LU1585245621.USD","SG9999015341.SGD","LU1941712348.USD","LU0266013472.USD","MRK","LU1066051225.USD","LU1066053197.SGD","BK4550","IE00BN8TJ469.HKD","MURA","IE00B4R5TH58.HKD","LU1116320737.USD","LU1069347547.HKD","IE00BJT1NW94.SGD","SG9999002224.SGD","LU0203345920.USD","LU0211331839.USD","LU1934455194.USD","BK4516","IE0009355771.USD","LU1989772840.SGD","IE00BJJMRZ35.SGD","SG9999015358.SGD","LU1291159041.SGD","LU2361045086.USD","LU0320765489.SGD","LU0234572021.USD","LU0058720904.USD","PROC","LU0861579265.USD","LU1116320901.HKD","SG9999014575.USD","SG9999002232.USD","LU0122379950.USD","LU1989771016.USD","LU1066051811.HKD","LU2361044865.SGD","SG9999001176.USD","SG9999014542.SGD","LU0006306889.USD","SG9999001440.SGD"],"gpt_icon":1},{"id":"2520518536","title":"This Week's Unlock Schedule: SOLV, APE, and OM to Experience Large One-time Vesting","url":"https://stock-news.laohu8.com/highlight/detail?id=2520518536","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520518536?lang=en_us&edition=fundamental","pubTime":"2025-03-17 08:37","pubTimestamp":1742171820,"startTime":"0","endTime":"0","summary":"BlockBeats News, March 17th, according to Token Unlocks data, tokens such as SOLV, APE, OM, etc., will see a large unlocking this week, including:Solv Protocol (SOLV) will unlock approximately 117 mil","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/285821","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["BK4139","OM","BK4198","APE","BK4108","BK4144","SOLV","APE.AU","BK7143","AM","MURA","BK4082","QAI"],"gpt_icon":0},{"id":"2518087779","title":"Mural Oncology Q4 2024 GAAP EPS $(2.01) Misses $(1.96) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2518087779","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518087779?lang=en_us&edition=fundamental","pubTime":"2025-03-12 04:03","pubTimestamp":1741723438,"startTime":"0","endTime":"0","summary":"Mural Oncology Q4 2024 GAAP EPS $(2.01) Misses $(1.96) Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44262081/mural-oncology-q4-2024-gaap-eps-2-01-misses-1-96-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Mural Oncology Q4 2024 GAAP EPS $(2.01) Misses $(1.96) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MURA"],"gpt_icon":0},{"id":"2518725779","title":"Mural Oncology Plc: Cash Runway Extended Into Q1 2026 Through Operational Efficiencies","url":"https://stock-news.laohu8.com/highlight/detail?id=2518725779","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518725779?lang=en_us&edition=fundamental","pubTime":"2025-03-12 04:01","pubTimestamp":1741723313,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250311:nFWN3PU174:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MURA","BK4139"],"gpt_icon":0},{"id":"2512159386","title":"Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2512159386","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512159386?lang=en_us&edition=fundamental","pubTime":"2025-02-18 20:00","pubTimestamp":1739880000,"startTime":"0","endTime":"0","summary":"About Mural Oncology. Contact:. Katie Sullivan. katie.sullivan@muraloncology.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mural-oncology-present-td-cowen-120000099.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4566","COWN","BK4207","TD","BK4139","MURA","BK4127"],"gpt_icon":0},{"id":"2510331345","title":"We Think Mural Oncology (NASDAQ:MURA) Needs To Drive Business Growth Carefully","url":"https://stock-news.laohu8.com/highlight/detail?id=2510331345","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510331345?lang=en_us&edition=fundamental","pubTime":"2025-02-11 23:55","pubTimestamp":1739289302,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly.So should Mural Oncology  shareholders be worried about its cash burn?In this article, we define cash burn as its annual  free cash flow, which is the amount of money a company spends each year to fund its growth. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.When Might Mural Oncology Run Out Of Money?Since it has a market capitalisation of US$76m, Mural Oncology's US$141m in cash burn equates to about 184% of its market value. That suggests the company may have some funding difficulties, and we'd be","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/think-mural-oncology-nasdaq-mura-155502238.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NQmain","USJW.SI","PSQ","IE00B3QW5Z07.USD","NVIW.SI","IE00B64PRP62.GBP","SQQQ","IE00BGHQF748.EUR","QLD","BK4139",".IXIC","NDAQ","MNQmain","USAW.SI","TQQQ","TSYW.SI","BK4585","BK4112","IE00BKPKM429.USD","MURA","LU2095319765.USD","QID","BK4588","LU2210149790.SGD","LU2210150020.SGD"],"gpt_icon":1},{"id":"2509256877","title":"Promising Prospects for Mural Oncology: Buy Rating Justified by Strong Pipeline and Financial Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2509256877","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509256877?lang=en_us&edition=fundamental","pubTime":"2025-02-06 04:45","pubTimestamp":1738788316,"startTime":"0","endTime":"0","summary":"In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Mural Oncology Plc (MURA – Research Report), with a price targe...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-prospects-for-mural-oncology-buy-rating-justified-by-strong-pipeline-and-financial-position?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-prospects-for-mural-oncology-buy-rating-justified-by-strong-pipeline-and-financial-position?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MURA"],"gpt_icon":0},{"id":"2506372173","title":"Mural Oncology Initiated at Buy by Jones Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2506372173","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506372173?lang=en_us&edition=fundamental","pubTime":"2025-01-27 21:28","pubTimestamp":1737984480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MURA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 27, 2025 08:28 ET (13:28 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MURA"],"gpt_icon":0},{"id":"2502570368","title":"Mural Oncology Advances Drug Pipeline and Extends Runway","url":"https://stock-news.laohu8.com/highlight/detail?id=2502570368","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502570368?lang=en_us&edition=fundamental","pubTime":"2025-01-10 20:30","pubTimestamp":1736512206,"startTime":"0","endTime":"0","summary":"Mural Oncology Plc ( ($MURA) ) just unveiled an announcement. Mural Oncology announced significant progress in its drug development pipeline, highl...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mural-oncology-advances-drug-pipeline-and-extends-runway?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mural-oncology-advances-drug-pipeline-and-extends-runway?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MURA"],"gpt_icon":0},{"id":"2502735350","title":"Mural Oncology Achieves Required Overall Survival Events in Trial, Extends Cash Runway","url":"https://stock-news.laohu8.com/highlight/detail?id=2502735350","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502735350?lang=en_us&edition=fundamental","pubTime":"2025-01-10 06:42","pubTimestamp":1736462526,"startTime":"0","endTime":"0","summary":"Mural Oncology  said Thursday it achieved 75% of the required overall survival events for the planned interim analysis in its ARTISTRY-7 trial evaluating nemvaleukin with pembrolizumab for platinum-resistant ovarian cancer.The company said it extended its cash runway projection into Q1 2026.Mural also expanded its pipeline in Q4 2024 by nominating two new development candidates for its interleukin-18 and interleukin-12 programs, it added.The company said it anticipates filing an Investigational New Drug application or Clinical Trial Application for a phase 1 trial of MURA-8518 in Q4 2025.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","MURA"],"gpt_icon":0},{"id":"2502027473","title":"Mural Oncology Plc -Company Extends Cash Runway Projection Into Q1 2026 Through Operational Efficiencies","url":"https://stock-news.laohu8.com/highlight/detail?id=2502027473","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502027473?lang=en_us&edition=fundamental","pubTime":"2025-01-10 05:42","pubTimestamp":1736458937,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250109:nFWN3O50AI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MURA","BK4139"],"gpt_icon":0},{"id":"2502614022","title":"Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2502614022","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502614022?lang=en_us&edition=fundamental","pubTime":"2025-01-10 05:00","pubTimestamp":1736456400,"startTime":"0","endTime":"0","summary":"Readouts for two late-stage, potentially registrational trials of nemvaleukin alfa expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Preliminary ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/09/3007342/0/en/Mural-Oncology-Highlights-Pipeline-Progress-and-Anticipated-2025-Catalysts.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","CTA","BK4007","LU2065732104.USD","MURA","OS","PROC","BK4139","PRGS"],"gpt_icon":0},{"id":"2488979938","title":"Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2488979938","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488979938?lang=en_us&edition=fundamental","pubTime":"2024-12-04 05:15","pubTimestamp":1733260500,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass and DUBLIN, Dec.  03, 2024  (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapie","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/03/2991069/0/en/Mural-Oncology-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4112","IE00BGHQF748.EUR","BK4585","IE00B64PRP62.GBP","BK4139","LU2095319765.USD","IE00B3QW5Z07.USD",".IXIC","IE00BKPKM429.USD","LU2210149790.SGD","MURA","BK4588","NDAQ"],"gpt_icon":1}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":57,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MURA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MURA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MURA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.5,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":4,"updateTime":1742961600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MURA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MURA","date":"2025-04-17","current":-0.32442,"percent":0.661184,"low":-0.567064,"twenty":-0.42226,"median":-0.354323,"eighty":-0.301829,"high":-0.133414,"avg":-0.358663,"sd":0.076815,"marketCap":41692464},"quantilePoints":[{"date":"2024-01-05","current":-0.481599,"twenty":-0.478881,"median":-0.474804,"eighty":-0.470727,"marketCap":94630786},{"date":"2024-01-12","current":-0.410251,"twenty":-0.486355,"median":-0.471406,"eighty":-0.445585,"marketCap":80611410},{"date":"2024-01-19","current":-0.3423,"twenty":-0.481599,"median":-0.439979,"eighty":-0.393263,"marketCap":67259623},{"date":"2024-01-26","current":-0.394962,"twenty":-0.471406,"median":-0.400483,"eighty":-0.374577,"marketCap":77607258},{"date":"2024-02-02","current":-0.377974,"twenty":-0.468009,"median":-0.394962,"eighty":-0.374577,"marketCap":74269311},{"date":"2024-02-09","current":-0.361836,"twenty":-0.439979,"median":-0.387742,"eighty":-0.372878,"marketCap":71098262},{"date":"2024-02-16","current":-0.422992,"twenty":-0.422992,"median":-0.393263,"eighty":-0.372878,"marketCap":83114870},{"date":"2024-02-23","current":-0.394962,"twenty":-0.419594,"median":-0.394962,"eighty":-0.374237,"marketCap":77607258},{"date":"2024-03-01","current":-0.449322,"twenty":-0.440489,"median":-0.397934,"eighty":-0.375256,"marketCap":88288687},{"date":"2024-03-08","current":-0.463762,"twenty":-0.455438,"median":-0.398359,"eighty":-0.376785,"marketCap":91125942},{"date":"2024-03-15","current":-0.409401,"twenty":-0.455438,"median":-0.402181,"eighty":-0.377804,"marketCap":80444513},{"date":"2024-03-22","current":-0.371179,"twenty":-0.454589,"median":-0.401757,"eighty":-0.376785,"marketCap":72934133},{"date":"2024-03-28","current":-0.403798,"twenty":-0.451361,"median":-0.400058,"eighty":-0.375086,"marketCap":83766622},{"date":"2024-04-05","current":-0.375246,"twenty":-0.449322,"median":-0.398359,"eighty":-0.374978,"marketCap":77843730},{"date":"2024-04-12","current":-0.350774,"twenty":-0.445245,"median":-0.39751,"eighty":-0.372198,"marketCap":72766965},{"date":"2024-04-19","current":-0.291224,"twenty":-0.441508,"median":-0.394962,"eighty":-0.366932,"marketCap":60413503},{"date":"2024-04-26","current":-0.287961,"twenty":-0.440319,"median":-0.393263,"eighty":-0.354313,"marketCap":59736601},{"date":"2024-05-03","current":-0.311618,"twenty":-0.439979,"median":-0.38392,"eighty":-0.342979,"marketCap":64644141},{"date":"2024-05-10","current":-0.309986,"twenty":-0.43845,"median":-0.382221,"eighty":-0.327769,"marketCap":64305690},{"date":"2024-05-17","current":-0.343069,"twenty":-0.428768,"median":-0.378823,"eighty":-0.318307,"marketCap":65833885},{"date":"2024-05-24","current":-0.316611,"twenty":-0.420444,"median":-0.375426,"eighty":-0.318307,"marketCap":60756722},{"date":"2024-05-31","current":-0.295445,"twenty":-0.417386,"median":-0.374577,"eighty":-0.316082,"marketCap":56694991},{"date":"2024-06-07","current":-0.294563,"twenty":-0.413309,"median":-0.372878,"eighty":-0.310639,"marketCap":56525752},{"date":"2024-06-14","current":-0.291035,"twenty":-0.410081,"median":-0.371179,"eighty":-0.308355,"marketCap":55848797},{"date":"2024-06-21","current":-0.286626,"twenty":-0.409401,"median":-0.368234,"eighty":-0.301829,"marketCap":55002603},{"date":"2024-06-28","current":-0.270751,"twenty":-0.409061,"median":-0.366932,"eighty":-0.301173,"marketCap":51956305},{"date":"2024-07-05","current":-0.264578,"twenty":-0.407601,"median":-0.361535,"eighty":-0.298647,"marketCap":50771634},{"date":"2024-07-12","current":-0.28839,"twenty":-0.40373,"median":-0.353221,"eighty":-0.295445,"marketCap":55341081},{"date":"2024-07-15","current":-0.28839,"twenty":-0.403661,"median":-0.351997,"eighty":-0.295445,"marketCap":55341081},{"date":"2024-08-02","current":-0.30691,"twenty":-0.403593,"median":-0.350774,"eighty":-0.295445,"marketCap":58895095},{"date":"2024-08-09","current":-0.28839,"twenty":-0.402946,"median":-0.34384,"eighty":-0.294206,"marketCap":55341081},{"date":"2024-08-16","current":-0.309698,"twenty":-0.402097,"median":-0.3423,"eighty":-0.293345,"marketCap":53669674},{"date":"2024-08-23","current":-0.322479,"twenty":-0.400738,"median":-0.337815,"eighty":-0.294206,"marketCap":55884613},{"date":"2024-08-30","current":-0.320512,"twenty":-0.399365,"median":-0.334277,"eighty":-0.294563,"marketCap":55543853},{"date":"2024-09-06","current":-0.314613,"twenty":-0.398685,"median":-0.332486,"eighty":-0.294916,"marketCap":54521574},{"date":"2024-09-13","current":-0.309698,"twenty":-0.398359,"median":-0.332045,"eighty":-0.295445,"marketCap":53669674},{"date":"2024-09-20","current":-0.340176,"twenty":-0.398359,"median":-0.331604,"eighty":-0.295445,"marketCap":58951452},{"date":"2024-09-27","current":-0.2979,"twenty":-0.398019,"median":-0.327395,"eighty":-0.295798,"marketCap":51625115},{"date":"2024-10-04","current":-0.314613,"twenty":-0.396762,"median":-0.323462,"eighty":-0.296327,"marketCap":54521574},{"date":"2024-10-11","current":-0.336243,"twenty":-0.395369,"median":-0.327395,"eighty":-0.296327,"marketCap":58269932},{"date":"2024-10-18","current":-0.362789,"twenty":-0.394962,"median":-0.331327,"eighty":-0.296956,"marketCap":62870190},{"date":"2024-10-25","current":-0.343125,"twenty":-0.394282,"median":-0.332398,"eighty":-0.2979,"marketCap":59462592},{"date":"2024-10-31","current":-0.350008,"twenty":-0.393263,"median":-0.332486,"eighty":-0.298033,"marketCap":60655251},{"date":"2024-11-08","current":-0.33231,"twenty":-0.391781,"median":-0.332486,"eighty":-0.298629,"marketCap":57588412},{"date":"2024-11-15","current":-0.387645,"twenty":-0.387286,"median":-0.33396,"eighty":-0.298901,"marketCap":59610428},{"date":"2024-11-22","current":-0.374316,"twenty":-0.385465,"median":-0.33526,"eighty":-0.298973,"marketCap":57560786},{"date":"2024-11-29","current":-0.443181,"twenty":-0.393263,"median":-0.336243,"eighty":-0.298973,"marketCap":68150604},{"date":"2024-12-06","current":-0.455399,"twenty":-0.39564,"median":-0.339193,"eighty":-0.299866,"marketCap":70029443},{"date":"2024-12-13","current":-0.415413,"twenty":-0.398359,"median":-0.339541,"eighty":-0.300736,"marketCap":63880516},{"date":"2024-12-20","current":-0.348769,"twenty":-0.398359,"median":-0.340176,"eighty":-0.301829,"marketCap":53632305},{"date":"2024-12-27","current":-0.353212,"twenty":-0.398359,"median":-0.340176,"eighty":-0.301829,"marketCap":54315519},{"date":"2025-01-03","current":-0.355433,"twenty":-0.398359,"median":-0.34173,"eighty":-0.302962,"marketCap":54657126},{"date":"2025-01-10","current":-0.405416,"twenty":-0.398359,"median":-0.343097,"eighty":-0.304593,"marketCap":62343284},{"date":"2025-01-17","current":-0.409859,"twenty":-0.401077,"median":-0.344248,"eighty":-0.306233,"marketCap":63026498},{"date":"2025-01-24","current":-0.435406,"twenty":-0.40373,"median":-0.345715,"eighty":-0.306728,"marketCap":66954979},{"date":"2025-01-31","current":-0.418745,"twenty":-0.408369,"median":-0.346075,"eighty":-0.30678,"marketCap":64392927},{"date":"2025-02-07","current":-0.492053,"twenty":-0.409859,"median":-0.34988,"eighty":-0.307074,"marketCap":75665959},{"date":"2025-02-14","current":-0.473171,"twenty":-0.413191,"median":-0.351865,"eighty":-0.307731,"marketCap":72762299},{"date":"2025-02-21","current":-0.468728,"twenty":-0.415413,"median":-0.353212,"eighty":-0.307731,"marketCap":72079085},{"date":"2025-02-28","current":-0.406527,"twenty":-0.418745,"median":-0.354323,"eighty":-0.308355,"marketCap":62514088},{"date":"2025-03-07","current":-0.39653,"twenty":-0.416524,"median":-0.35567,"eighty":-0.308355,"marketCap":60976856},{"date":"2025-03-14","current":-0.486438,"twenty":-0.418745,"median":-0.357655,"eighty":-0.308355,"marketCap":62514088},{"date":"2025-03-21","current":-0.518803,"twenty":-0.425409,"median":-0.358364,"eighty":-0.309698,"marketCap":66673486},{"date":"2025-03-28","current":-0.180978,"twenty":-0.428742,"median":-0.357873,"eighty":-0.308355,"marketCap":23258192},{"date":"2025-04-04","current":-0.164891,"twenty":-0.425409,"median":-0.357272,"eighty":-0.30691,"marketCap":21190797},{"date":"2025-04-11","current":-0.133414,"twenty":-0.422992,"median":-0.355433,"eighty":-0.303717,"marketCap":17145595},{"date":"2025-04-17","current":-0.32442,"twenty":-0.42226,"median":-0.354323,"eighty":-0.301829,"marketCap":41692464}],"updateTime":1745262886930}}}